Utilizing real-world synthetic control arms to demonstrate the comparative effectiveness of pralsetinib in non-small cell lung cancer patients: an interview with Sreeram Ramagopalan

12 Jul 2022

Written by Sreeram Ramagopalan (F. Hoffmann-La Roche)

Comparative effectiveness research Decision science Health technology assessment Journal articles Market access Oncology and hematology Peek Behind the Paper Real-world evidence

In this interview with Sreeram Ramagopalan of F. Hoffman La Roche (Basel, Switzerland), we discuss his recent publication in Nature communications, which examined how quantitative bias analysis can be utilized to overcome common issues in indirect treatment comparisons in non-small cell lung cancer patients by utilizing real-world data (RWD). Biography Sreeram Ramagopalan is the Global Head for Real-World Evidence for Market Access at F. Hoffmann-La Roche (Basel, Switzerland). Along with his team, Sreeram is involved in strategically planning and executing RWD studies for market access utilizations, such as health technology assessment (HTA) submissions. Could you explain what the...